Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine

Self/Nonself - Immune Recognition and Signaling

Volumn 2, Issue 2, 2011, Pages 114-119

  Fasano, Candida ^a   Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Anti B19 erythrovirus vaccine; B19 erythrovirus; Fifth disease; Low similarity peptides; Viral vrs human peptide overlap

Indexed keywords

HUMAN PARVOVIRUS B19 VACCINE; PEPTIDE; POLYPROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ARTICLE; AUTOIMMUNITY; CROSS REACTION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; PROTEIN ANALYSIS; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EID: 83155161250     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.2.2.16190     Document Type: Article

References (62)

1. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15:485-505.
2. Weir E. Parvovirus B19 infection: fifth disease and more. CMAJ 2005; 172:743.
3. Takahashi Y, Murai C, Ishii T, Sugamura K, Sasaki T. Human parvovirus B19 in rheumatoid arthritis. Int Rev Immunol 1998; 17:309-21.
4. Kaneko H, Shimura K, Nishida K, Fujiwara Y, Matsumoto Y, Kuroda J, et al. Pure red cell aplasia caused by parvovirus B19 in two patients without chronic hemolysis. J Infect Chemother 2011; 17:268-71.
5. de Haan TR, van den Akker ES, Porcelijn L, Oepkes D, Kroes AC, Walther FJ. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76-81.
6. Kondo H, Mori A, Watanabe J, Takada J, Takahashi Y, Iwasaki H. Pure red cell aplasia associated with par-vovirus B19 infection in T-large granular lymphocyte leukemia. Leuk Lymphoma 2001; 42:1439-43.
7. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010; 362:1248-9.
8. Mogensen TH, Jensen JM, Hamilton-Dutoit S, Larsen CS. Chronic hepatitis caused by persistent parvovirus B19 infection. BMC Infect Dis 2010; 10:246.
9. Kerr JR, Barah F, Chiswick ML, McDonnell GV, Smith J, Chapman MD, et al. Evidence for the role of demyelination, HLA-DR alleles and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J Neurol Neurosurg Psychiatry 2002; 73:739-46.
10. Aguilar-Bernier M, Bassas-Vila J, Torné-Gutiérrez JI, Martínez-García G, Aragoneses-Fraile H, Miranda-Romero A. Presence of perineuritis in a case of papular purpuric gloves and socks syndrome associated with mononeuritis multiplex attributable to B19 parvovirus. J Am Acad Dermatol 2006; 54:896-9.
11. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis 2009; 48:1713-23.
12. Seishima M, Shibuya Y, Suzuki S. Hyperthyroidism associated with human parvovirus B19 infection. Clin Exp Dermatol 2009; 34:439-40.
13. Adamson LA, Fowler LJ, Clare-Salzler MJ, Hobbs JA. Parvovirus B19 infection in Hashimoto's thyroiditis, papillary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 2011; 21:411-7.
14. Podymow T, Muhtadie L. Pregnancy-associated parvo-virus B19 infection causing postinfectious glomerulo-nephritis. Hypertens Pregnancy 2010; 29:429-33.
15. Obeid KM, Effendi AR, Khatib R. Association of parvovirus B19 infection with glomerulonephritis in an immunocompetent host: a case report. Scand J Infect Dis 2009; 41:890-2.
16. Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus 2010; 19:783-92.
17. Tsay GJ, Zouali M. Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochem Pharmacol 2006; 72:1453-9.
18. Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion 2010; 50:1712-21.
19. Bansal G P, Hatfield JA, Dunn FE, Kramer AA, Brady F, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993; 167:1034-44.
20. Franssila R, Hokynar K, Hedman K. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19. J Infect Dis 2001; 183:805-9.
21. Tsai CC, Tzang BS, Chiang SY, Hsu GJ, Hsu TC. Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. J Biomed Sci 2009; 16:14.
22. Wu CH, Yeh LS, Huang H, Arminski L, Castro-Alvear J, Chen Y, et al. The Protein Information Resource. Nucleic Acids Res 2003; 31:345-7.
23. Landsteiner K, van der Scheer J. On the serological specificity of peptides. III. J Exp Med 1939; 69:705-19.
24. Kanduc D. Immunogenicity in peptide-immunothera-py: from self/nonself to similar/dissimilar sequences. In: Sigalov AB, Editor. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease, Landes Biosciences, Austin TX 2008; 198-207.
25. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33:703-7.
26. Kanduc D. "Self-nonself" peptides in the design of vaccines. Curr Pharm Des 2009; 15:3283-9.
27. Kanduc D. Protein information content resides in rare peptide segments. Peptides 2010; 31:983-8.
28. Kanduc D. The self/nonself issue: A confrontation between proteomes. Self Nonself 2010; 1:255-8.
29. Kusalik A, Bickis M, Lewis C, Li Y, Lucchese G, Marincola FM, et al. Widespread and ample peptide overlapping between HCV and Homo sapiens pro-teomes. Peptides 2007; 28:1260-7.
30. Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29:1755-66.
31. Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 2009; 8:65-76.
32. Kanduc D, Serpico R, Lucchese A, Shoenfeld Y. Correlating low-similarity peptide sequences and HIV B-cell epitopes. Autoimmun Rev 2008; 7:291-6.
33. Polimeno L, Mittelman A, Gennero L, Ponzetto A, Lucchese G, Stufano A, et al. Sub-epitopic dissection of HCV E1315-328HRM AWD MMM NWS PT sequence by similarity analysis. Amino Acids 2008; 34:479-84.
34. Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J Immunopathol Pharmacol 2009; 22:639-46.
35. Kanduc D. Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes. Biologics 2010; 4:245-61.
36. Ricco R, Kanduc D. Hepatitis B virus and Homo sapiens proteome-wide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins. Biologics 2010; 4:75-81.
37. Lucchese G, Stufano A, Kanduc D. Searching for an effective, safe and universal anti-HIV vaccine: finding the answer in just one short peptide. Self Nonself 2011; 2:49-54.
38. Lucchese G, Stufano A, Calabro' M, Kanduc D. Charting the peptide crossreactome between HIV-1 and the human proteome. Front Biosci 2011; 3:1385-400.
39. Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc Natl Acad Sci USA 2004; 101:11628-33.
40. Longo N, Wang Y, Pasquali M. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 1999; 84:2623-9.
41. Longo N, Langley SD, Griffin LD, Elsas LJ. Tw o mutations in the insulin receptor gene of a patient with leprechaunism: application to prenatal diagnosis. J Clin Endocrinol Metab 1995; 80:1496-501.
42. Moller DE, Cohen O, Yamaguchi Y, Assiz R, Grigorescu F, Eberle A, et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 1994; 43:247-55.
43. Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol 2011; 7:15-29.
44. Correia CT, Coutinho AM, Sequeira AF, Sousa IG, Lourenço Venda L, Almeida J P, et al. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav 2010; 9:841-8.
45. Zuffi E, Manaresi E, Gallinella G, Gentilomi GA, Venturoli S, Zerbini M, et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 2001; 14:151-8.
46. + T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79:12117-21.
47. + T-cell response to parvovirus B19 infection in HLA-A*2402-positive individuals. J Virol 2006; 80:6697-701.
48. + T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopa-thy. PLoS One 2008; 3:2361.
49. Kaikkonen L, Söderlund-Venermo M, Brunstein J, Schou O, Panum Jensen I, Rousseau S, et al. Diagnosis of human parvovirus B19 infections by detection of epitope-type-specific VP2 IgG. J Med Virol 2001; 64:360-5.
50. Kaikkonen L, Lankinen H, Harjunpää I, Hokynar K, Söderlund-Venermo M, Oker-Blom C, et al. Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection. J Clin Microbiol 1999; 37:3952-6.
51. Tolfvenstam T, Oxenius A, Price DA, Shacklett BL, Spiegel HM, Hedman K, et al. Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol 2001; 75:540-3.
52. Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol 2006; 80:12017-24.
53. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, et al. The immune epitope database and analysis resource: from vision to blueprint. PloS Biol 2005; 3:91.
54. Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 2004; 22:749-55.
55. Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin Exp Rheumatol 2002; 20:767-71.
56. Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK, et al. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States 1990-2003. Vaccine 2008; 26:1166-72.
57. Geier DA, King PG, Sykes LK, Geier MR. RotaTeq vaccine adverse events and policy considerations. Med Sci Monit 2008; 14:9-16.
58. Siegrist CA. Mechanisms underlying adverse reactions to vaccines. J Comp Path 2007; 137:46-50.
59. Silbergeld EK. Mercury, vaccines and autism, revisited. Am J Public Health 2008; 98:1350-1.
60. Trost B, Lucchese G, Stufano A, Bickis M, Kusalik A, Kanduc D. No human protein is exempt from bacterial motifs, not even one. Self Nonself 2010; 1:328-34.
61. Lucchese G, Stufano A, Kanduc D. Proteome-guided search for influenza A B-cell epitopes. FEMS Immunol Med Microbiol 2009; 57:88-92.
62. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00379938.